Johnson & Johnson (JNJ) Non-Current Debt (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Non-Current Debt came in at $37.5 billion in Q1 2026, down 2.16% year-on-year from $38.4 billion in Q1 2025, and down 4.85% quarter-over-quarter from $39.4 billion in Q4 2025.
Johnson & Johnson (JNJ) Non-Current Debt (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Non-Current Debt across 18 years of filings, most recently posting $37.5 billion for Q1 2026.
- Non-Current Debt for Q1 2026 came in at $37.5 billion, down 2.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.5 billion (down 2.16% YoY), and the FY2025 annual result was $39.4 billion, up 28.67% from the prior year.
- Non-Current Debt came in at $37.5 billion for Q1 2026 at Johnson & Johnson, down from $39.4 billion in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $39.4 billion in Q4 2025 to a low of $25.1 billion in Q1 2024.
- The 5-year median for Non-Current Debt is $31.0 billion (2024), against an average of $31.9 billion.
- Across the five-year window, Non-Current Debt decreased 28.19% in 2024 and jumped 52.92% in 2025, its largest moves.
- Johnson & Johnson's Non-Current Debt stood at $27.6 billion in 2022, then slipped by 6.24% to $25.9 billion in 2023, then increased by 18.43% to $30.7 billion in 2024, then advanced by 28.67% to $39.4 billion in 2025, then declined by 4.85% to $37.5 billion in 2026.
- The last three Non-Current Debt figures came in at $37.5 billion (Q1 2026), $39.4 billion (Q4 2025), and $39.4 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -18.89 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 39.37 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 37.53 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 64.53 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 46.67 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 51.89 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 20.86 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 60.57 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 42.15 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 37.53 Bn |
| Mar 29, 2026 | 37.53 Bn |
| Dec 28, 2025 | 39.44 Bn |
| Dec 28, 2025 | 39.44 Bn |
| Sep 28, 2025 | 39.41 Bn |
| Sep 28, 2025 | 39.41 Bn |
| Jun 29, 2025 | 39.24 Bn |
| Jun 29, 2025 | 39.24 Bn |
| Mar 30, 2025 | 38.36 Bn |
| Mar 30, 2025 | 38.36 Bn |
| Dec 29, 2024 | 30.65 Bn |
| Dec 29, 2024 | 30.65 Bn |
| Sep 29, 2024 | 31.29 Bn |
| Sep 29, 2024 | 31.29 Bn |
| Jun 30, 2024 | 31.64 Bn |
| Jun 30, 2024 | 31.64 Bn |
| Mar 31, 2024 | 25.08 Bn |
| Mar 31, 2024 | 25.08 Bn |
| Dec 31, 2023 | 25.88 Bn |
| Dec 31, 2023 | 25.88 Bn |